Conference Proceeding

Challenges in diabetes and clinical trials: An xpedited solution

Dr. Vineeta Sharma

Diabetes mellitus is one of the most common chronic diseases throughout the world, and it’s incidence and prevalence is significantly growing. Diabetes being a complex metabolic disorder brings lots of challenges in front of clinicians and physicians to conduct and commence clinical trials. Moreover, anti-diabetic drugs increase cardiovascular risk hence requires larger, longer and expensive clinical trials. Xpedite is your ally for navigating the complexities of clinical trial management as we offer full trial management service that includes SOP write up, site selection, feasibility, site initiation and visit to staff training for sample collection, handling, storage and shipment.

In addition to that, we are committed to providing clinical data management (CDM) solution that emphasizes transparency, integrity and accountability as much as speed and accuracy. Our CDM team delivers results that are source-verified, reproducible and cost-efficient. As the product of the clinical development process, clinical data is recognized to be the key corporate asset and provides critical evidence of a drug’s efficacy and safety and of its potential economic value to the market. From database build to database lock, Xpedite is committed to customizing data management solutions that emphasize transparency, integrity and accountability as much as speed and accuracy. We deliver results that are source-verified, reproducible and cost-efficient. Xpedite is a team of clinicians, data managers, clinical trial managers, scientists and experts in diabetes and metabolic disorders field, thus we offer a competitive landscape and the best solution to your problem. To summarize, our deep understanding in the field and flexible clinical trial and data management solution meet your need for speed, without compromising data integrity or accuracy.

Published: 17 October 2017

Copyright:

Copyright: © 2017 Dr. Vineeta Sharma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.